Evidence map›Paper›PMID 36571557›Full record

ArticleCancer2023

Multicenter study of pediatric Epstein-Barr virus-negative monomorphic post solid organ transplant lymphoproliferative disorders.

Zeinab A M Afify, Mary M Taj, Manuela Orjuela-Grimm, Kavitha Srivatsa, Tamara P Miller, Holly J Edington, Mansi Dalal, Joanna Robles, James B Ford, Matthew J Ehrhardt and 13 more

Open access · greenAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. EBV and post-transplant lymphoproliferative disorder: a complex relationship.Hematology. American Society of Hematology. Education Program · 2024
    Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 15 institutions in 2 countries.

Zeinab A M AfifyPrimary Children's Hospital, University of Utah, Salt Lake City, Utah, USA.ORCID 0000-0001-7238-0389
Mary M TajThe Royal Marsden Hospital, Sutton, London, UK.
Manuela Orjuela-GrimmColumbia University Medical Center, New York, New York, USA.ORCID 0000-0002-7385-7561
Kavitha SrivatsaThe Royal Marsden Hospital, Sutton, London, UK.
Tamara P MillerEmory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, Georgia, USA.ORCID 0000-0003-4250-5376
Holly J EdingtonEmory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, Georgia, USA.ORCID 0000-0001-7315-5917
Mansi DalalUniversity of Florida Health Science Center, Gainesville, Florida, USA.
Joanna RoblesDuke University School of Medicine, Durham, North Carolina, USA.
James B FordUniversity of Nebraska Medical Center, Omaha, Nebraska, USA.
Matthew J EhrhardtSt. Jude Children's Research Hospital, Memphis, Tennessee, USA.
Tonya J UredaSt. Jude Children's Research Hospital, Memphis, Tennessee, USA.
Jeremy D RubinsteinCincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
Sarah McCormackCincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
Julie M RiversSeattle Children's Hospital, Seattle, Washington, USA.
Karen M ChisholmSeattle Children's Hospital, Seattle, Washington, USA.
Madison K KavanaughDepartment of Pediatrics, UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Andrew J BukowinskiDepartment of Pediatrics, University of Pittsburgh, School of Medicine, Pittsburgh, Pennsylvania, USA.
Erika D FriehlingDepartment of Pediatrics, University of Pittsburgh, School of Medicine, Pittsburgh, Pennsylvania, USA.
Maegan C FordColumbia University Medical Center, New York, New York, USA.
Sonika N ReddyColumbia University Medical Center, New York, New York, USA.
Lianna J MarksStanford University School of Medicine, Palo Alto, California, USA.
Christine Moore SmithVanderbilt University Medical Center, Nashville, Tennessee, USA.
Clinton C MasonDepartment of Pediatrics, University of Utah, Salt Lake City, Utah, USA.
Columbia University Irving Medical Center · USCincinnati Children's Hospital Medical Center · USEmory University · USRoyal Marsden Hospital · GBSeattle Children's Hospital · USSt. Jude Children's Research Hospital · USUniversity of Pittsburgh · USChildren's Hospital of Pittsburgh · USDuke University · USPalo Alto University · USPrimary Children's Hospital · USUniversity of Florida Health Science Center · USUniversity of Nebraska Medical Center · USUniversity of Utah · USVanderbilt University Medical Center · US

Funding

VECTOR CORE FACILITYP30CA047904 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Jessie Nedrow · 1988 to 2026
$158.0M
NCI NIH HHS P30 CA047904
6 · The paper itself

Abstract

backgroundPediatric Epstein-Barr virus-negative monomorphic post solid organ transplant lymphoproliferative disorder [EBV(-)M-PTLD] comprises approximately 10% of M-PTLD. No large multi-institutional pediatric-specific reports on treatment and outcome are available.

methodsA multi-institutional retrospective review of solid organ recipients diagnosed with EBV(-)M-PTLD aged ≤21 years between 2001 and 2020 in 12 centers in the United States and United Kingdom was performed, including demographics, staging, treatment, and outcomes data.

resultsThirty-six patients were identified with EBV(-)M-PTLD. Twenty-three (63.9%) were male. Median age (range) at transplantation, diagnosis of EBV(-)M-PTLD, and interval from transplant to PTLD were 2.2 years (0.1-17), 14 years (3.0-20), and 8.5 years (0.6-18.3), respectively. Kidney (n = 17 [47.2%]) and heart (n = 13 [36.1%]) were the most commonly transplanted organs. Most were Murphy stage III (n = 25 [69.4%]). Lactate dehydrogenase was elevated in 22/34 (64.7%) and ≥2 times upper limit of normal in 11/34 (32.4%). Pathological diagnoses included diffuse large B-cell lymphoma (n = 31 [86.1%]) and B-non-Hodgkin lymphoma (B-NHL) not otherwise specified (NOS) (n = 5 [13.9%]). Of nine different regimens used, the most common were: pediatric mature B-NHL-specific regimen (n = 13 [36.1%]) and low-dose cyclophosphamide, prednisone, and rituximab (n = 9 [25%]). Median follow-up from diagnosis was 3.0 years (0.3-11.0 years). Three-year event-free survival (EFS) and overall survival (OS) were 64.8% and 79.9%, respectively. Of the seven deaths, six were from progressive disease.

conclusionsEFS and OS were comparable to pediatric EBV(+) PTLD, but inferior to mature B-NHL in immunocompetent pediatric patients. The wide range of therapeutic regimens used directs our work toward developing an active multi-institutional registry to design prospective studies. PLAIN LANGUAGE SUMMARY: Pediatric Epstein-Barr virus-negative monomorphic post solid organ transplant lymphoproliferative disorders (EBV(-)M-PTLD) have comparable outcomes to EBV(+) PTLD, but are inferior to diffuse large B-cell lymphoma in immunocompetent pediatric patients. The variety of treatment regimens used highlights the need to develop a pediatric PTLD registry to prospectively evaluate outcomes. The impact of treatment regimen on relapse risk could not be assessed because of small numbers. In the intensive pediatric B-non-Hodgkin lymphoma chemoimmunotherapy group, 11 of 13 patients remain alive in complete remission after 0.6 to 11 years.

Indexed as

Epstein-Barr Virus InfectionsLymphoma, Large B-Cell, DiffuseLymphoma, Non-HodgkinLymphoproliferative DisordersMyeloproliferative DisordersOrgan TransplantationChildFemaleHerpesvirus 4, HumanHumansMaleProspective StudiesRetrospective StudiesEBV negativemonomorphicpediatricPTLDsolid organ transplant

Identifiers

PMID36571557
PMCPMC11200327
OpenAlexW4312179896

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.